Biotechnology company · MRNA

Moderna
clinical trial
pipeline

Registry checked

Published

Infectious Disease is the largest mapped primary therapeutic group, with 15 of 30 active trials. This ranking covers mapped groups only. mRNA-1403 is linked to 1 distinct active study, with 1 Phase 3. Intismeran Autogene is linked to 2 distinct active studies, with 1 Phase 1, 1 Phase 2.

Phase 2 study NCT05095727 in Glycogen Storage Disease lists estimated primary completion on 30 November 2026. Phase 3 study NCT07496450 in Influenza lists estimated primary completion on 28 January 2027. These are registry estimates of primary completion, not confirmed results announcements or overall study completion.

Active trial mix

Lead-sponsor scope

30active trials
as lead sponsor
  • Phase 19
  • Phase 212
  • Phase 32
  • Phase 44
  • Phase not recorded3

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

02 Oct 2026 – 31 Oct 2026 · UTC

Recorded changes

96 trials30 completed days
Recruitment statusPrimary completionEnrolmentFirst observedOther

Highlighted changes 03

Select an example to see what changed

01Recruitment status
Not yet recruitingRecruiting

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age

NCT07808697 · ClinicalTrials.gov
Recorded by ComplyRx
30 Oct 2026
Registry last updated
29 Oct 2026

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-10-020000000
2026-10-030000221
2026-10-040000000
2026-10-050000000
2026-10-060000000
2026-10-070000000
2026-10-080000000
2026-10-090000000
2026-10-100000221
2026-10-110000000
2026-10-120000000
2026-10-130000000
2026-10-140000000
2026-10-150000000
2026-10-160000000
2026-10-170000000
2026-10-180000000
2026-10-190000000
2026-10-200000000
2026-10-210000000
2026-10-220000000
2026-10-230000000
2026-10-241100021
2026-10-250000000
2026-10-260000000
2026-10-270000000
2026-10-282000022
2026-10-290000000
2026-10-301000011
2026-10-310000000
Type totals4100496 distinct

02 / Drugs & programmes

Explore the pipeline

6 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

Elasomeran

Canonical investigational asset

2
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 20
  • Phase 30
  • Phase 42
  • Phase not recorded0
Studied condition
SARS-CoV-2
Next primary completion
Not reported
Open drug

mRNA-1010

Canonical investigational asset

2
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 11
  • Phase 20
  • Phase 30
  • Phase 41
  • Phase not recorded0
Studied condition
Seasonal Influenza
Next primary completion
Not reported
Open drug

Intismeran Autogene

Canonical investigational asset

2
Active trials
0
Recruiting trials
Trial phases
Highest: Phase 2
  • Phase 11
  • Phase 21
  • Phase 30
  • Phase 40
  • Phase not recorded0
Studied condition
Melanoma · Solid Tumors
Next primary completion
Not reported
Open drug

mRNA-1189

Canonical investigational asset

2
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 2
  • Phase 11
  • Phase 21
  • Phase 30
  • Phase 40
  • Phase not recorded0
Studied condition
Epstein-Barr Virus · Epstein-Barr Virus Infection
Next primary completion
Not reported
Open drug

mRNA-3927

Canonical investigational asset

2
Active trials
2
Recruiting trials
Trial phases
Highest: Phase 2
  • Phase 10
  • Phase 22
  • Phase 30
  • Phase 40
  • Phase not recorded0
Studied condition
Propionic Acidemia
Next primary completion
31 August 2027 · estimated
Open drug

mRNA-1273 Variant-containing Formulation

Canonical investigational asset

1
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 20
  • Phase 30
  • Phase 41
  • Phase not recorded0
Studied condition
SARS-CoV-2
Next primary completion
Not reported
Open drug

25 of 30 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

6 selected programmes · accepted investigational links cover 25 of 30 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

Moderna trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
6 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)
mRNA-3745

NCT05095727

Phase 2 · Active, not recruiting

Trial source and qualifications

A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 4 inspected observations were not displayed.

4 candidate observations · 0 shown · 0 recorded after primary completion · 4 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

4 inspected observations omitted. At most three verified observations are shown, not full history.

    Start: 01 Jun 2022 · actual
    Primary completion: 30 Nov 2026 · estimated
    Study completion: 30 Nov 2026 · estimated

    2021202220232024202520262027202820292030
    A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults
    mRNA-1018-H5

    NCT07496450

    Phase 3 · Active, not recruiting

    Trial source and qualifications

    A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

    2 candidate observations · 2 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    Up to three verified eligible observations in the bounded history window.

    • status flip · Recorded 2026-08-11 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
    • enrollment change · Recorded 2026-08-11 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

    Start: 23 Mar 2026 · actual
    Primary completion: 28 Jan 2027 · estimated
    Study completion: 28 Jan 2027 · estimated

    2021202220232024202520262027202820292030
    Nova 301
    mRNA-1403

    NCT06592794

    Phase 3 · Active, not recruiting

    Trial source and qualifications

    A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 7 inspected observations were not displayed.

    7 candidate observations · 0 shown · 0 recorded after primary completion · 7 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    7 inspected observations omitted. At most three verified observations are shown, not full history.

      Start: 24 Sept 2024 · actual
      Primary completion: 15 Feb 2027 · estimated
      Study completion: 15 Feb 2027 · estimated

      2021202220232024202520262027202820292030
      A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.
      mRNA-1647

      NCT05683457

      Phase 2 · Active, not recruiting

      Trial source and qualifications

      A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.

      Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 3 inspected observations were not displayed.

      4 candidate observations · 1 shown · 0 recorded after primary completion · 3 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      3 inspected observations omitted. At most three verified observations are shown, not full history.

      • pc date moved · Recorded 2026-08-11 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

      Start: 05 Apr 2023 · actual
      Primary completion: 06 Mar 2027 · estimated
      Study completion: 06 Mar 2027 · estimated

      2021202220232024202520262027202820292030
      Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
      mRNA-3927

      NCT04159103

      Phase 2 · Recruiting

      Trial source and qualifications

      Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia

      Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

      2 candidate observations · 0 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      2 inspected observations omitted. At most three verified observations are shown, not full history.

        Start: 15 Apr 2021 · actual
        Primary completion: 31 Aug 2027 · estimated
        Study completion: 31 Aug 2027 · estimated

        2021202220232024202520262027202820292030
        A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age)
        mRNA-1982

        NCT07561294

        Phase 2 · Active, not recruiting

        Trial source and qualifications

        A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age)

        Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

        2 candidate observations · 2 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        Up to three verified eligible observations in the bounded history window.

        • enrollment change · Recorded 2026-08-03 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
        • status flip · Recorded 2026-08-03 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

        Start: 29 Apr 2026 · actual
        Primary completion: 09 Nov 2028 · estimated
        Study completion: 09 Nov 2028 · estimated

        2021202220232024202520262027202820292030

        Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

        6 selected of 10 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 0 actual primary completions, 0 untyped primary completions, 1 past estimates, 3 outside the horizon, 0 contradictory dates.

        04 / Therapeutic focus

        Where the activity is

        15

        active trials in Infectious Disease

        Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

        Active trials by primary therapeutic area

        • Infectious Disease15 trials
        • Oncology5 trials
        • Neurology1 trials
        • Unmapped8 trials
        • Healthy volunteers1 trials

        Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

        06 / Related companies

        All companies
        M

        Merck

        Shared indexed programme context · 1 selected asset

        T

        Takeda

        Shared indexed programme context · 1 selected asset

        Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

        Sources, scope and methodology

        ClinicalTrials.gov lead-sponsor scope

        Canonical current-owner attribution covers 117 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: ModernaTX, Inc.. Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion.

        ClinicalTrials.gov

        Attribution coverage

        117 distinct registry candidates produced 117 accepted studies. 0 mapped to other owners, 0 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 0 unverified, 0 identity-only and 0 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

        Indexed enrichment

        98 scoped records have indexed enrichment and 19 do not. Missing enrichment does not remove a trial from cohort counts.

        Scope observation

        The successful attribution check completed at 2026-11-01T01:16:56.603Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot a3a877e90044aabd72567e895b8fec903af9edf887e5fe99c757533c32854969.

        Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

        Dated canonical-attribution snapshot: 117 mapped lead-sponsored clinical studies across all statuses. 98 have indexed enrichment, 19 do not. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

        Keep following
        what matters.

        Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

        Build your watch

        Choose what to track in the watch builder.